Resources

 

Anxiety

• Cannabidiol, a Cannabis sativa constituent, as an anxiolytic drug (PubMed)
• Antidepressant-Like and Anxiolytic-Like Effects of Cannabidiol: A Chemical Compound of Cannabis Sativa (PubMed)
• Cannabidiol reduces the anxiety induced by simulated public speaking in treatment-naïve social phobia patients (PubMed)
• Neural basis of anxiolytic effects of cannabidiol (CBD) in generalized social anxiety disorder (PubMed)
• Effects of cannabidiol (CBD) on regional cerebral blood flow (PubMed)

Alzheimer’s

• Neuroprotective effect of cannabidiol, a non-psychoactive component from Cannabis sativa, on beta-amyloid-induced toxicity in PC12 cells (PubMed)
• Cannabidiol in vivo blunts beta-amyloid induced neuroinflammation by suppressing IL-1beta and iNOS expression (PubMed)
• Cannabidiol: A promising drug for neurodegenerative disorders? (PubMed)
• Cannabidiol Promotes Amyloid Precursor Protein Ubiquitination and Reduction of Beta Amyloid Expression in SHSY5YAPP+ Cells Through PPARγ Involvement (PubMed)
• Cannabinoids for treatment of Alzheimer’s disease: moving toward the clinic (Pub Med)

Addiction

• Cannabidiol reduces cigarette consumption in tobacco smokers (PubMed)
• Cannabidiol inhibits the reward-facilitating effect of morphine (PubMed)
• Cannabidiol, a nonpsychotropic component of cannabis, inhibits cue-induced heroin seeking and normalizes discrete mesolimbic neuronal disturbances (PubMed)
• Impact of Cannabis Use during Stabilization on Methadone Maintenance Treatment (PubMed)
• Comparison of cannabidiol, antioxidants, and diuretics in reversing binge ethanol-induced neurotoxicity (PubMed)
• Cannabidiol for the treatment of cannabis withdrawal syndrome (PubMed)

AIDS

• Cannabidiol inhibits growth and induces programmed cell death in kaposi sarcoma associated herpes virus-infected endothelium (PubMed)

Arthritis

• The nonpsychoactive cannabis constituent cannabidiol is an oral anti-arthritic therapeutic in murine collagen-induced arthritis (PubMed)

Atherosclerosis

• The potential use of cannabidiol in the therapy of metabolic syndrome (PubMed)

Cancer

• Cannabidiol as potential anticancer drug (PubMed)
• Cannabidiol inhibits angiogenesis by multiple mechanisms (PubMed)
• Cannabidiol inhibits cancer cell invasion via upregulation of tissue inhibitor of matrix metalloproteinases-1 (PubMed)
• Endocannabinoids in endocrine and related tumors (PubMed)
• A comparative study on cannabidiol-induced apoptosis in murine thymocytes and EL-4 thymoma cells (PubMed)
• TRPV2 activation induces apoptotic cell death in human T24 bladder cancer cells: a potential therapeutic target for bladder cancer (PubMed)
• Cannabis and Cannabinoids (PDQ®)Laboratory/Animal/Preclinical Studies(National Cancer Institute)

Lung Cancer

• Cannabidiol inhibits lung cancer cell invasion and metastasis via intercellular adhesion molecule-1C (PubMed)
• Decrease of plasminogen activator inhibitor-1 may contribute to the anti-invasive action of cannabidiol on human lung cancer cells (PubMed)

Prostate / Colon Cancer

• Towards the use of non-psychoactive cannabinoids for prostate cancer (PubMed)
• In Vitro Anticancer Activity of Plant-Derived Cannabidiol on Prostate Cancer Cell Lines (Scirp.org)
• Induction of apoptosis by cannabinoids in prostate and colon cancer cells is phosphatase dependent (PubMed)
• Chemopreventive effect of the non-psychotropic phytocannabinoid cannabidiol on experimental colon cancer (PubMed)

Breast Cancer

• Antitumor activity of plant cannabinoids with emphasis on the effect of cannabidiol on human breast carcinoma (PubMed)
• Cannabidiol induces programmed cell death in breast cancer cells by coordinating the cross-talk between apoptosis and autophagy (PubMed)
• Pathways mediating the effects of cannabidiol on the reduction of breast cancer cell proliferation, invasion, and metastasis (PubMed)
• Cannabidiol as a novel inhibitor of Id-1 gene expression in aggressive breast cancer cells (PubMed)

Brain Cancer

• Antitumor effects of cannabidiol, a non-psychoactive cannabinoid, on human glioma cell lines(PubMed)
• Systematic review of the literature on clinical and experimental trials on the antitumor effects of cannabinoids in gliomas (PubMed)
• Cannabidiol inhibits human glioma cell migration through a cannabinoid receptor independent mechanism (PubMed)
• Id-1 is a key transcriptional regulator of glioblastoma aggressiveness and a novel therapeutic target (PubMed)
• Triggering of the TRPV2 channel by cannabidiol sensitizes glioblastoma cells to cytotoxic chemotherapeutic agents (PubMed)
• Cannabidiol, a non-psychoactive cannabinoid compound, inhibits proliferation and invasion in U87-MG and T98G glioma cells through a multitarget effect (PubMed)
• Local delivery of cannabinoid-loaded microparticles inhibits tumor growth in a murine xenograft model of glioblastoma multiforme (PubMed)
• The Combination of Cannabidiol and Δ9-Tetrahydrocannabinol Enhances the Anticancer Effects of Radiation in an Orthotopic Murine Glioma Model

Leukemia

• Cannabidiol-induced apoptosis in human leukemia cells: A novel role of cannabidiol in the regulation of p22phox and Nox4 expression (PubMed)
• Cannabidiol-Induced Apoptosis in Human Leukemia Cells (PubMed)

 
^ Back to top of page

Skin Cancer

• Anticancer activity of anandamide in human cutaneous melanoma cells (PubMed)

Kaposi Sarcoma

• Cannabidiol inhibits growth and induces programmed cell death in kaposi sarcoma associated herpes virus-infected endothelium (PubMed)

Crohn’s & Stomach Problems

• Cannabidiol in inflammatory bowel diseases: a brief overview (PubMed)
• Cannabis finds its way into treatment of Crohn’s disease (PubMed)
• Cannabidiol reduces intestinal inflammation through the control of neuroimmune axis (PubMed)
• Cannabidiol, a safe and non-psychotropic ingredient of the marijuana plant Cannabis sativa, is protective in a murine model of colitis (PubMed)
• Topical and systemic cannabidiol improves trinitrobenzene sulfonic acid colitis in mice (PubMed)
• Hergenrather presents study of Crohn’s patients as a template for clinical research on Cannabis (O’Shaughnessy’s)

Depression

• Antidepressant-Like and Anxiolytic-Like Effects of Cannabidiol: A Chemical Compound of Cannabis Sativa (PubMed)
• The endocannabinoid system and the treatment of mood and anxiety disorders (PubMed)
• Antidepressant-Like effects of cannabidiol in mice: Possible involvement of 5-HT1A receptors (PubMed)
• Putative role of endocannabinoid signaling in the etiology of depression and actions of antidepressants (PubMed)
• The therapeutic potential of the endocannabinoid system for the development of a novel class of antidepressants (PubMed)

Diabetes

• Cannabidiol attenuates cardiac dysfunction, oxidative stress, fibrosis, and inflammatory and cell death signaling pathways in diabetic cardiomyopathy (PubMed)
• Diabetic retinopathy: Role of inflammation and potential therapies for anti-inflammation (PubMed)
• The endocannabinoid system in obesity and type 2 diabetes (PubMed)
• Cannabinoids and endocannabinoids in metabolic disorders with focus on diabetes (PubMed)
• Cannabinoid-mediated modulation of neuropathic pain and microglial accumulation in a model of murine type I diabetic peripheral neuropathic pain (PubMed)

Epilepsy/Seizure

• Report of a parent survey of cannabidiol-enriched cannabis use in pediatric treatment resistant epilepsy (PubMed)
• The non-psychotropic plant cannabinoids, cannabidivarin (CBDV) and cannabidiol (CBD), activate and desensitize transient receptor potential vanilloid 1 (TRPV1) channels in vitro: potential for the treatment of neuronal hyperexcitability (ACS Publications)
• Chronic administration of cannabidiol to healthy volunteers and epileptic patients (PubMed)
• Cannabidiol: Pharmacology and potential therapeutic role in epilepsy and other neuropsychiatric disorders (PubMed)
• Cannabidiol exerts anti-convulsant effects in animal models of temporal lobe and partial seizures (PubMed)
• Cannabidiol displays antiepileptiform and antiseizure properties in vitro and in vivo (PubMed)
• Hypnotic and anti-epileptic effects of cannabidiol (PubMed)
• CBD for children with Dravet’s and intractable seizures (Video)

Heart Disease

• Is the cardiovascular system a therapeutic target for cannabidiol? (PubMed)
• Acute administration of cannabidiol in vivo suppresses ischaemia-induced cardiac arrhythmias and reduces infarct size when given at reperfusion (PubMed)
• Cannabidiol attenuates cardiac dysfunction, oxidative stress, fibrosis, and inflammatory and cell death signaling pathways in diabetic cardiomyopathy (PubMed)
• The Effect of Cannabidiol on Ischemia/Reperfusion-Induced Ventricular Arrhythmias: The Role of Adenosine A1 Receptors (PubMed)
• Cannabidiol, a non-psychoactive Cannabis constituent, protects against myocardial ischemic reperfusion injury (PubMed)
• Endocannabinoids acting at cannabinoid-1 receptors regulate cardiovascular function in hypertension (PubMed)
• Oleamide: A fatty acid amide signaling molecule in the cardiovascular system? (PubMed)

Huntington’s

• Cannabinoids: Novel medicines for the treatment of Huntington’s disease (PubMed)
• Prospects for cannabinoid therapies in basal ganglia disorders (PubMed)

Inflammation

• Cannabidiol as an emergent therapeutic strategy for lessening the impact of inflammation on oxidative stress (PubMed)
• The endocannabinoid system: an emerging key player in inflammation (PubMed)
• Anti-inflammatory role of cannabidiol and O-1602 in cerulein-induced acute pancreatitis in mice (PubMed)
• Cannabinoids, endocannabinoids, and related analogs in inflammation (PubMed)
• Cannabidiol, a non-psychotropic plant-derived cannabinoid, decreases inflammation in a murine model of acute lung injury: role for the adenosine A(2A) receptor (PubMed)
• Cannabinoids suppress inflammatory and neuropathic pain by targeting α3 glycine receptors (PubMed)
• Diabetic retinopathy: Role of inflammation and potential therapies for anti-inflammation (PubMed)
• Cannabidiol reduces Aβ-induced neuroinflammation and promotes hippocampal neurogenesis through PPARγ involvement (PubMed)
• Cannabidiol attenuates high glucose-induced endothelial cell inflammatory response and barrier disruption (PubMed)
• Cannabidiol attenuates cisplatin-induced nephrotoxicity by decreasing oxidative/nitrosative stress, inflammation, and cell death (PubMed)
• Cannabinoids in clinical practice (PubMed)

Irritable Bowel

• Cannabidiol in inflammatory bowel diseases: A brief overview (PubMed)
• Cannabidiol reduces intestinal inflammation through the control of neuroimmune axis (PubMed)
• Clinical endocannabinoid deficiency (CECD): Can this concept explain therapeutic benefits of cannabis in migraine, fibromyalgia, irritable bowel syndrome and other treatment-resistant conditions? (PubMed)
• Beneficial effect of the non-psychotropic plant cannabinoid cannabigerol on experimental inflammatory bowel disease (Biochemical Pharmacology) (ScienceDirect)

Kidney Disease

• Cannabidiol attenuates cisplatin-induced nephrotoxicity by decreasing oxidative/nitrosative stress, inflammation, and cell death (PubMed)

Liver Disease

• The endocannabinoid system and liver diseases (PubMed)
• Cannabidiol causes activated hepatic stellate cell death through a mechanism of endoplasmic reticulum stress-induced apoptosis (PubMed)
• Therapeutic potential of cannabidiol against ischemia/reperfusion liver injury in rats (PubMed)
• Role of myeloid-derived suppressor cells in amelioration of experimental autoimmune hepatitis following activation of TRPV1 receptors by cannabidiol (PubMed)
• Cannabidiol improves brain and liver function in a fulminant hepatic failure-induced model of hepatic encephalopathy in mice (PubMed)

Metabolic Syndrome

• The potential use of cannabidiol in the therapy of metabolic syndrome (PubMed)

Migraine

• The endocannabinoid system and migraine (PubMed)

Mood Disorders

• Multiple mechanisms involved in the large-spectrum therapeutic potential of cannabidiol in psychiatric disorders (PubMed)
• The endocannabinoid system and the treatment of mood and anxiety disorders (PubMed)
• The endocannabinoid system and psychiatric disorders (PubMed)
• The endocannabinoid system in the regulation of emotions throughout lifespan: A discussion on therapeutic perspectives (PubMed)
• Effects of cannabidiol (CBD) on regional cerebral blood flow (PubMed)

Motion Sickness

• Motion sickness, stress and the endocannabinoid system (PubMed)

MS / Multiple Sclerosis

• Cannabidiol provides long-lasting protection against the deleterious effects of inflammation in a viral model of multiple sclerosis: A role for A2A receptors (PubMed)
• Nabiximols in the treatment of spasticity, pain and urinary symptoms due to multiple sclerosis (PubMed)

 
^ Back to top of page

Nausea

• Cannabidiol, a non-psychotropic component of cannabis, attenuates vomiting and nausea-like behavior via indirect agonism of 5-HT(1A) somatodendritic autoreceptors in the dorsal raphe nucleus (PubMed)
• Regulation of nausea and vomiting by cannabinoids (PubMed)

Neurodegeneration

• Cannabidiol: A promising drug for neurodegenerative disorders? (PubMed)
• Cannabidiol for neurodegenerative disorders: Important new clinical applications for this phytocannabinoid? (PubMed)
• Cannabidiol normalizes caspase 3, synaptophysin, and mitochondrial fission protein DNM1L expression levels in rats with brain iron overload: implications for neuroprotection (Pub Med)

Obesity

• The endocannabinoid system in obesity and type 2 diabetes (PubMed)
• Role of the endocannabinoid system in abdominal obesity and the implications for cardiovascular risk (PubMed)
• Cannabinoids and endocannabinoids in metabolic disorders with focus on diabetes (PubMed)

Osteoporosis

• Cannabinoid receptors as target for treatment of osteoporosis: A tale of two therapies (PubMed)
• Cannabinoids and bone: Friend or foe? (PubMed)
• Cannabinoid receptor type 1 protects against age-related osteoporosis by regulating osteoblast and adipocyte differentiation in marrow stromal cells (PubMed)
• The endovanilloid/endocannabinoid system: A new potential target for osteoporosis therapy (PubMed)
• The endovanilloid/endocannabinoid system in human osteoclasts: Possible involvement in bone formation and resorption (PubMed)
• Cannabinoid receptors and the regulation of bone mass (PubMed)

Parkinson’s

• Prospects for cannabinoid therapies in basal ganglia disorders (PubMed)
• Cannabinoids provide neuroprotection against 6-hydroxydopamine toxicity in vivo and in vitro: relevance to Parkinson’s disease (PubMed)
• Cannabidiol can improve complex sleep-related behaviors associated with rapid eye movement sleep behavior disorder in Parkinson’s disease patients: a case series (PubMed)
• Cannabidiol for the treatment of psychosis in Parkinson’s disease (PubMed)
• Effects of cannabidiol in the treatment of patients with Parkinson’s disease: an exploratory double-blind trial. (PubMed 2014)
• Dorsolateral Prefrontal Cortex N-Acetylaspartate/Total Creatine (NAA/tCr) Loss in Male Recreational Cannabis Users (Research Gate/PubMed 2007)
• Cannabidiol for the treatment of psychosis in Parkinson’s disease. (PubMed)

Prion/Mad Cow disease

• Non-psychoactive cannabidiol prevents prion accumulation and protects neurons against prion toxicity (PubMed)

PTSD

• Cannabidiol blocks long-lasting behavioral consequences of predator threat stress: Possible involvement of 5HT1A receptors (PubMed)
• Stress switches cannabinoid type-1 (CB1) receptor-dependent plasticity from LTD to LTP in the bed nucleus of the stria terminalis (PubMed)
• Cannabinoid modulation of fear extinction brain circuits: A novel target to advance anxiety treatment (PubMed)
• The endocannabinoid system and extinction learning (PubMed)
• Cannabinoids and traumatic stress modulation of contextual fear extinction and GR expression in the amygdala-hippocampal-prefrontal circuit (PubMed)
• The anxiolytic effect of cannabidiol on chronically stressed mice depends on hippocampal neurogenesis: Involvement of the endocannabinoid system (PubMed)

Rheumatism

• Cannabidiol as an emergent therapeutic strategy for lessening the impact of inflammation on oxidative stress (PubMed)

Schizophrenia

• Cannabidiol, a Cannabis sativa constituent, as an antipsychotic drug (PubMed)
• Cannabidiol as a potential treatment for psychosis (PubMed)
• Cannabidiol enhances anandamide signaling and alleviates psychotic symptoms of schizophrenia (PubMed)
• Medical use of cannabis. Cannabidiol: A new light for schizophrenia? (PubMed)
• A critical review of the antipsychotic effects of cannabidiol: 30 years of a translational investigation (PubMed)
• Cannabinoids and schizophrenia: Therapeutic prospects (PubMed)
• Antipsychotic-like effects of cannabidiol and rimonabant: Systematic review of animal and human studies (PubMed)
• Cannabidiol monotherapy for treatment-resistant schizophrenia (PubMed)
• Cannabis with high cannabidiol content is associated with fewer psychotic experiences (PubMed)

Skin conditions

• Cannabidiol exerts sebostatic and anti-inflammatory effects on human sebocytes (PubMed)
• The endocannabinoid system of the skin in health and disease: Novel perspectives and therapeutic opportunities (PubMed)
• Epigenetic control of skin differentiation genes by phytocannabinoids (PubMed)
• A novel control of human keratin expression: cannabinoid receptor 1-mediated signaling down-regulates the expression of keratins K6 and K16 in human keratinocytes in vitro and in situ (PubMed)
• Endocannabinoids modulate human epidermal keratinocyte proliferation and survival via the sequential engagement of cannabinoid receptor-1 and transient receptor potential vanilloid1 (PubMed)
• Topical cannabinoid agonists. An effective new possibility for treating chronic pruritus (PubMed)

Sleep disorders

• The non-psychoactive Cannabis constituent cannabidiol is a wake-inducing agent (PubMed)
• Cannabis, pain, and sleep: Lessons from therapeutic clinical trials of Sativex, a cannabis based medicine (PubMed)

Stress

• Endogenous cannabinoid signaling is essential for stress adaptation (PubMed)
• Regulation of endocannabinoid signaling by stress: Implications for stress-related affective disorders (PubMed)
• Downregulation of endocannabinoid signaling in the hippocampus following chronic unpredictable stress (PubMed)
• Stress regulates endocannabinoid-CB1 receptor signaling (PubMed)
• Chronic Stress Impairs α1-Adrenoceptor-Induced Endocannabinoid-Dependent Synaptic Plasticity in the Dorsal Raphe Nucleus (Pub Med)
• Endocannabinoid-mediated modulation of stress responses: Physiological and pathophysiological significance (PubMed)

 
^ Back to top of page